Probiotix Health PLC
F:X90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (0.2), the stock would be worth €-0 (101% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -16.4 | €0.07 |
0%
|
| Industry Average | 0.2 | €-0 |
-101%
|
| Country Average | 0.1 | €-0 |
-101%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
P
|
Probiotix Health PLC
F:X90
|
14.5m EUR | -16.4 | -17.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 18.5 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 18.6 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 16.2 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 30.1 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 16 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 119.3 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 11.9 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.1 |
| 70th Percentile | 0.2 |
| Max | 2 143.8 |
Other Multiples
Probiotix Health PLC
Glance View
ProBiotix Health Plc develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. The company is headquartered in York, North Yorkshire and currently employs 2 full-time employees. The company went IPO on 2022-03-31. The firm develops probiotics to tackle cardiovascular disease and other lifestyle conditions. The company manufactures cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (LP-LDL). ProBiotix commercializes LP-LDL as an ingredient and in a range of white and own-label products under its CholBiome range. The CholBiome portfolio consists of four products, namely CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH. LP-LDL helps to improve blood lipid profiles and blood pressure. The firm's development pipeline is fuelled by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact human physiology and bring potential health benefits. These platforms are applicable across a range of other human diseases. The firm is focused on identifying and developing microbial strains, compounds, and formulations for use in the nutraceutical industry.
